This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

NextDocs And Microsoft Mobilize Clinical Trials With Trial Exchange And Windows 8

CONSHOHOCKEN, Pa., March 20, 2013 /PRNewswire/ --  NextDocs, the global leader in compliance solutions for the life sciences industry, today demonstrated how its newly launched Trial Exchange solution combined with Windows 8 addresses the critical needs of life sciences companies in securely and efficiently managing clinical trials in today's highly global and mobile operating environments.

Trial Exchange, the newest product available on the NextDocs platform, provides an easy-to-use interface for investigators and site staff to access and contribute essential documents for clinical trials.  The documents and workflows can then be managed within the NextDocs eTMF solution.  NextDocs Trial Exchange can be accessed through the web browser or through a native Windows 8 app.

In an online demonstration, Microsoft and NextDocs showed how the combination of Trial Exchange and Windows 8 addresses the need for greater mobility, security, compliance and collaboration in clinical trial management. 

"We live in an ever more global, mobile and connected world that can pose many business challenges – but also presents opportunities.  The native Windows 8 app for Trial Exchange allows life sciences professionals to readily access and contribute documents from any device anywhere in the world.  It makes clinical trial document management solutions easy-to-use without sacrificing compliance, security or mobility," said Matt Walz, Chief Technology Officer at NextDocs.    

The proliferation of mobile devices and tablets presents new compliance and security challenges for life sciences companies.  Switching back and forth between unintegrated devices also tends to lower productivity and increase costs.  These problems can magnify when companies start to bring external partners into the clinical trial process.

Trial Exchange and Windows 8 can solve these issues.  The solutions allow trial site staff to contribute documents to an established eTMF work stream, receive and complete tasks generated by the sponsor, view document statuses, and retrieve documents on demand – all within the industry standard SharePoint environment. Unlike many existing clinical portals, Trial Exchange plugs directly into the eTMF without additional routing, thus ensuring sponsor/CRO quality and document management processes in clinical site documents.

The Microsoft and NextDocs demonstration is available via a webinar at  The two companies will also demonstrate the solution live at the ShareFEST conference in Philadelphia in April 2013. To register for ShareFEST, please visit

About NextDocs CorporationNextDocs is the global leader in providing compliance software solutions including quality management software, regulatory document management, and clinical portals. NextDocs solutions enable businesses in regulated industries to achieve compliance with FDA and other agencies while automating processes, improving efficiency, and dramatically reducing costs. NextDocs' customers include pharmaceutical companies, biotechs, medical device companies, and CROs. For more information on NextDocs Corporation and its software solutions, visit

For further information, contact:

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs